Literature DB >> 16931937

Comparative analysis of T-cell turnover and homeostatic parameters in HIV-infected patients with discordant immune-virological responses to HAART.

Giulia Marchetti1, Andrea Gori, Anna Casabianca, Mauro Magnani, Fabio Franzetti, Mario Clerici, Carlo-Federico Perno, Antonella d'Arminio Monforte, Massimo Galli, Luca Meroni.   

Abstract

OBJECTIVE: Inadequate CD4 cell count recovery despite full HIV RNA control occurs in 30% of HAART-treated HIV-infected patients. A better understanding of the relationship between T-cell dynamics and the HIV intracellular reservoir in HIV-infected patients failing to recover CD4 cell count following long-term HAART, is required.
METHODS: In a cross-sectional study T-cell turnover and homeostatic parameters featuring discordant responses were investigated in 27 immunologic non-responders (INR; CD4 count, < or = 200 cells/microl; HIV RNA, < or = 50 copies/ml), 15 virological non-responders (VNR; CD4 count, > or = 350 cells/microl; HIV RNA, > or = 10 000) and 22 full responders (FR; CD4 count, > or = 500 cells/microl; HIV RNA, < or = 50 copies/ml).
RESULTS: INR displayed significantly higher activated CD38CD8 than FR (P < 0.05) and was comparable to VNR (P > 0.05). As compared with VNR and FR, INR displayed the highest level of proliferating Ki67CD4 and apoptotic CD4 cells (P < 0.05). VNR presented lower proliferation and apoptosis than FR and INR. INR displayed the lowest levels of naive T cells (P < 0.05) and a predominant memory pattern. Despite the memory/activated/apoptotic phenotype, INR showed a statistically non-significant reduction in T-cell receptor excision circles (TREC) compared to FR (P > 0.05), and substantially heightened interleukin (IL)-7 (P < 0.05), while VNR showed higher naive T-cell counts and TREC. Moreover, the reservoir of infected CD4 cells was increased in INR, with a trend toward highest intracellular HIV DNA within total, naive and memory CD4 cells.
CONCLUSIONS: The lack of CD4 cell count recovery in INR seems to reflect a highly activated apoptotic T-cell compartment, with elevated IL-7 and thymic impairment. High levels of intracellular HIV-DNA in INR could be strictly involved in the lack of T-cell reconstitution. Immune correlates of an ultimate direction of the response to HAART, could be exploited in clinical practice for the most effective management of discordant patients, to amend immune imbalances and to improve clinical outcome.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16931937     DOI: 10.1097/01.aids.0000242819.72839.db

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  56 in total

1.  Minocycline suppresses activation of nuclear factor of activated T cells 1 (NFAT1) in human CD4+ T cells.

Authors:  Gregory L Szeto; Joel L Pomerantz; David R M Graham; Janice E Clements
Journal:  J Biol Chem       Date:  2011-01-31       Impact factor: 5.157

2.  Maraviroc intensification in patients with suppressed HIV viremia has limited effects on CD4+ T cell recovery and gene expression.

Authors:  Nadejda Beliakova-Bethell; Sonia Jain; Christopher H Woelk; Mallory D Witt; Xiaoying Sun; Steven M Lada; Celsa A Spina; Miguel Goicoechea; Steffney E Rought; Richard Haubrich; Michael P Dubé
Journal:  Antiviral Res       Date:  2014-04-24       Impact factor: 5.970

3.  Discordance between peripheral and colonic markers of inflammation during suppressive ART.

Authors:  Richard M Dunham; Ivan Vujkovic-Cvijin; Steven A Yukl; Mara J Broadhurst; Pʼng Loke; Rebecca G Albright; Joseph K Wong; Michael M Lederman; Ma Somsouk; Peter W Hunt; Jeffrey N Martin; Steven G Deeks; Joseph M McCune
Journal:  J Acquir Immune Defic Syndr       Date:  2014-02-01       Impact factor: 3.731

4.  Inflammatory cytokines drive CD4+ T-cell cycling and impaired responsiveness to interleukin 7: implications for immune failure in HIV disease.

Authors:  Carey L Shive; Joseph C Mudd; Nicholas T Funderburg; Scott F Sieg; Benjamin Kyi; Doug A Bazdar; Davide Mangioni; Andrea Gori; Jeffrey M Jacobson; Ari D Brooks; Jeffrey Hardacre; John Ammori; Jacob D Estes; Timothy W Schacker; Benigno Rodriguez; Michael M Lederman
Journal:  J Infect Dis       Date:  2014-02-28       Impact factor: 5.226

5.  Measurement of soluble inflammatory mediators in cerebrospinal fluid of human immunodeficiency virus-positive patients at distinct stages of infection by solid-phase protein array.

Authors:  Thorsten Nolting; Antje Lindecke; Eleni Koutsilieri; Matthias Maschke; Ingo-W Husstedt; Sieghart Sopper; Olaf Stüve; Hans-Peter Hartung; Gabriele Arendt
Journal:  J Neurovirol       Date:  2009-09       Impact factor: 2.643

6.  Treating HIV-1 Infection: What Might the Future Hold?

Authors:  Mathias Lichterfeld; Kimon C Zachary
Journal:  Ther Adv Chronic Dis       Date:  2011-09       Impact factor: 5.091

7.  Interleukin-7 promotes HIV persistence during antiretroviral therapy.

Authors:  Claire Vandergeeten; Rémi Fromentin; Sandrina DaFonseca; Mariam B Lawani; Irini Sereti; Michael M Lederman; Moti Ramgopal; Jean-Pierre Routy; Rafick-Pierre Sékaly; Nicolas Chomont
Journal:  Blood       Date:  2013-04-15       Impact factor: 22.113

Review 8.  Microbial translocation, immune activation, and HIV disease.

Authors:  Nichole R Klatt; Nicholas T Funderburg; Jason M Brenchley
Journal:  Trends Microbiol       Date:  2012-10-11       Impact factor: 17.079

9.  Incident tuberculosis during antiretroviral therapy contributes to suboptimal immune reconstitution in a large urban HIV clinic in sub-Saharan Africa.

Authors:  Sabine M Hermans; Agnes N Kiragga; Petra Schaefer; Andrew Kambugu; Andy I M Hoepelman; Yukari C Manabe
Journal:  PLoS One       Date:  2010-05-07       Impact factor: 3.240

10.  Low cholesterol? Don't brag yet ... hypocholesterolemia blunts HAART effectiveness: a longitudinal study.

Authors:  María Jose Míguez; John E Lewis; Vaughn E Bryant; Rhonda Rosenberg; Ximena Burbano; Joel Fishman; Deshratn Asthana; Rui Duan; Nair Madhavan; Robert M Malow
Journal:  J Int AIDS Soc       Date:  2010-07-13       Impact factor: 5.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.